This morning, biotechnology firms Genentech and Xoma announced that they stopped testing their experimental psoriasis drug Raptiva for rheumatoid arthritis.
FORBES: Magazine Article
2.
Amylin Pharmaceuticals (AMLN), Xoma(XOMA) and Jazz Pharmaceuticals (JAZZ) are among companies selling stock to raise cash in recent weeks.
FORBES: For Biotech, 'Fail' is Making a Big Comeback